Shanghai Henlius Biotech Inc
HKEX:2696
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.5
23.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Shanghai Henlius Biotech Inc
Other Current Liabilities
Shanghai Henlius Biotech Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shanghai Henlius Biotech Inc
HKEX:2696
|
Other Current Liabilities
¥663.2m
|
CAGR 3-Years
43%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Other Current Liabilities
¥1.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Other Current Liabilities
¥1.8B
|
CAGR 3-Years
38%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Other Current Liabilities
¥1.9B
|
CAGR 3-Years
53%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Other Current Liabilities
¥2.5B
|
CAGR 3-Years
23%
|
CAGR 5-Years
55%
|
CAGR 10-Years
58%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Other Current Liabilities
¥121.8m
|
CAGR 3-Years
33%
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
|
Shanghai Henlius Biotech Inc
Glance View
In the heart of China's bustling financial district, Shanghai Henlius Biotech Inc. stands proud as a beacon of innovation in the biopharmaceutical industry. Founded in 2010, Henlius has rapidly grown to become a notable player in the development of monoclonal antibodies, with a focus on oncology, autoimmune disorders, and ophthalmic conditions. The company's business model is rooted in its robust research and development capabilities, which are supported by strategic partnerships and a dedicated pipeline. By harnessing state-of-the-art technology and a global talent pool, Henlius crafts biosimilar and innovative biological drugs designed to meet the escalating health needs across the globe. With a strong focus on cutting-edge R&D, they have successfully commercialized several key products that have gained regulatory approval, allowing them to penetrate both domestic and international markets. Revenue flows into Henlius through a diversified portfolio that stretches beyond drug development to encompass manufacturing and sales partnerships. By leveraging their fully-integrated biopharmaceutical platform, Henlius not only develops its proprietary medications but also collaborates with other pharmaceutical giants to bring products to market efficiently. These collaborations often translate into licensing agreements and royalties, which provide Henlius with recurring income streams. The company's ability to navigate complex regulatory environments and its strategic expansion into global markets – including Europe, Southeast Asia, and Latin America – further reinforces its revenue-generating capacity. Thus, Henlius stands as a testament to the power of strategic ingenuity and cutting-edge science in the ever-evolving landscape of global healthcare.
See Also
What is Shanghai Henlius Biotech Inc's Other Current Liabilities?
Other Current Liabilities
663.2m
CNY
Based on the financial report for Dec 31, 2023, Shanghai Henlius Biotech Inc's Other Current Liabilities amounts to 663.2m CNY.
What is Shanghai Henlius Biotech Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
23%
Over the last year, the Other Current Liabilities growth was -27%. The average annual Other Current Liabilities growth rates for Shanghai Henlius Biotech Inc have been 43% over the past three years , 23% over the past five years .
You don't have any saved screeners yet
